Krystal Biotech (NASDAQ:KRYS) Given Buy Rating at Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS – Free Report) in a research report released on Tuesday, Benzinga reports. They currently have a $204.00 price target on the stock, up from their prior price target of $178.00. Other research analysts have also recently issued reports about the stock. William Blair […]

Related Keywords

United States ,Suma Krishnan ,Stifel Nicolaus ,William Blair ,Kathryn Romano ,Krystal Biotech Company Profile ,First Light Asset Management ,Krystal Biotech Inc ,Jennison Associates ,Blackrock Inc ,Securities Exchange Commission ,Vanguard Group Inc ,Citigroup ,Krystal Biotech ,Free Report ,Biotech Trading Down ,Get Free Report ,Exchange Commission ,Street Corp ,Light Asset Management ,Krystal Biotech Daily ,Nasdaq Krys ,Krys ,Medical ,Reiterated Rating ,